EUVIMEDEUVIMED entdecken
Open Access

Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo

Hongying Bao iD, Manxiang Wu iD, Jie Xing iD, Zihou Li iD, Yuenan Zhang iD, Aiguo Wu iD, Juan Li iD

Science Advances · 23.08.2024 · 10 (34)

DOI: 10.1126/sciadv.adq0703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 23.08.2024. Verfasst von Hongying Bao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, Laboratory of Advan…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Idiopathic Pulmonary Fibrosis, Nanoparticles, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stem cell therapy is being explored as a potential treatment for idiopathic pulmonary fibrosis (IPF), but its effectiveness is hindered by factors like reactive oxygen species (ROS) and inflammation in fibrotic lungs. Moreover, the distribution, migration, and survival of transplanted stem cells are still unclear, impeding the clinical advancement of stem cell therapy. To tackle these challenges, we fabricate AuPtCoPS trimetallic-based nanocarriers (TBNCs), with enzyme-like activity and plasmid loading capabilities, aiming to efficiently eradicate ROS, facilitate delivery of therapeutic genes, and ultimately improve the therapeutic efficacy. TBNCs also function as a computed tomography contrast agent for tracking mesenchymal stem cells (MSCs) during therapy. Accordingly, we enhanced the antioxidant stress and anti-inflammatory capabilities of engineered MSCs and successfully visualized their biological behavior in IPF mice in vivo. Overall, this study provides an efficient and forward-looking treatment approach for IPF and establishes a framework for a stem cell–based therapeutic system aimed at addressing lung disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsIdiopathic Pulmonary FibrosisNanoparticlesMesenchymal Stem Cell TransplantationAnimalsMiceHumansDisease Models, AnimalReactive Oxygen Species

Substanzen

Reactive Oxygen Species

Autor:innen und Institutionen

  • Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Material…
  • Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi 315300, Ch…

ORCID-Profile: Hongying Bao, Manxiang Wu, Jie Xing, Zihou Li, Yuenan Zhang, Aiguo Wu, Juan Li

Zitieren

APA

Bao, H., Wu, M., Xing, J., Li, Z., Zhang, Y., Wu, A., & Li, J. (2024). Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo. Science Advances, 10(34). https://doi.org/10.1126/sciadv.adq0703

Vancouver

Bao H, Wu M, Xing J, Li Z, Zhang Y, Wu A, et al. Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo. Science Advances. 2024;10(34). doi:10.1126/sciadv.adq0703

BibTeX
@article{Bao2024,
  author = {Bao, Hongying and Wu, Manxiang and Xing, Jie and Li, Zihou and Zhang, Yuenan and Wu, Aiguo and Li, Juan},
  title = {Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {34},
  doi = {10.1126/sciadv.adq0703}
}
Kostenlos starten →